An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

Trial Profile

An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 May 2015

At a glance

  • Drugs Selegiline (Primary) ; Tadalafil (Primary)
  • Indications Erectile dysfunction; Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 23 Apr 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 08 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top